I found the article really interesting. Enlarging the time window for treatment would allow the physicians to make a more accurate evaluation of the patient and, consequently, to set up the best therapy.
I have a banal question. The study highlights that the intervention group benefits from the treatment for all the categories of the Rankin scale, except for death. I was wondering about the reason: is this strategy efficacious only in slightly compromised patents?
Thanks for the answer and thanks for your work!
Q&A has ended
Diederik Dippel, MD, PhD
Senior Consultant in Neurology at the Erasmus Medical Center
Charles Majoie, MD, PhD
Chief of Neuroradiology at the Academic Medical Center Amsterdam
Wim H van Zwam, MD, PhD
Experienced Neurointerventionalist at the Maastricht University Medical Center
A van der Lugt , MD
Professor of Neuroradiology and Head/Neck Radiology at Erasmus MC
Olvert Berkhemer , MD
Ph.D. student on the MR CLEAN trial
Puck Fransen, MD/PhD student
PhD student with MR CLEAN trial
Joel Geerling, MD, PhD
Neurologist and Postdoctoral Research Fellow at BIDMC & Harvard Medical School
Minjee Kim, MD
Neurocritical care fellow at MGH/BWH/HMS
Chana Sacks, MD
General Internist, Massachusetts General Hospital, Research Fellow, Brigham and Women's Hospital
Mike Moore, DO
Family Medicine Resident at Madigan Army Medical Center
Medical Student at The Commonwealth Medical College Class of 2018
MD Candidate at OUWB; Founder/CEO of Surgerati
- All Questions & Answers
- Question: More clinically compromised patients?